Elgan Pharma

Executive Summary

Elgan Pharma is an Israeli biotechnology company specializing in late-stage development of non-invasive therapies for preterm infants, a critically underserved population with high morbidity and mortality. The company's lead programs address two major complications of prematurity: gastrointestinal immaturity (ELGN-GI) and retinopathy of prematurity (ELGN-EYE). Both therapies are locally delivered agents that modulate inflammation and oxidative stress, aiming to improve survival and long-term quality of life. With both programs in Phase 3, Elgan Pharma is uniquely positioned to address significant unmet needs in neonatology, gastroenterology, and ophthalmology.

Upcoming Catalysts (preview)

• TBDTop-line data from ELGN-GI Phase 3 trial55% success
• TBDTop-line data from ELGN-EYE Phase 3 trial55% success
• TBDPartnership or licensing deal for commercial rights40% success